Inotek Plummets On Glaucoma Phase III Failure
Shares in Inotek Pharmaceuticals went into freefall on Jan. 3 on news that its lead product had failed in a Phase III trial in glaucoma patients.
You may also be interested in...
Positive Phase III data for Aerie's second glaucoma drug candidate Roclatan – which will support a US FDA submission in the first half of 2018 – have boosted the California company's M&A allure.
A couple of unexpected events for pimavanserin mean that Acadia will drop its development for major depressive disorder and have to wait a little longer to hear if it can launch the product for dementia-related psychosis, a large potential indication.
The US FDA has given the go-ahead for marketing of ViiV healthcare’s novel HIV drug just as the EMA removes the accelerated assessment status from its application there.